Abstracts / The Breast 20 (2011) S12–S55S44

negative and HER2 negative disease. In a patients with a first diagnosis ofrecurrent breast cancer between 2001 and 2008, inmultivariate regressionanalyses, HR negativity (P ¼ 0.001), HER2 negativity (P ¼ 0.001), history ofadjuvant anthracycline and/or taxane containing chemotherapy (P¼ 0.02),shorter relapse free interval (P¼ 0.001) and presence of visceral metastasis(P ¼ 0.02) were significantly associated with poor prognosis. Whenpatients were categorized into 4 subgroups by the expression of HR andHER-2 status, the duration of survival was significantly worse among theHR-/HER2- subtype than other subtypes (1.4 years for HR-/HER2-, 4.2 yearsfor HR+/HER2-, 5.1 years for HR+/HER2+ and 5.0 years for HR-/HER2+; P<0.001). The prognosis of patients with recurrent breast cancer wasimproved over time following the introduction of AIs and trastuzumab, butHR negativity and HER2 negativity were significantly associated with poorprognosis as well as other traditional prognostic factors. New targettherapy is required to improve the prognosis of patients with HR-/HER2-breast cancer.

PO95

METASTATIC MALE BREAST CANCER

Irina KhachaturyanNational Center of Oncology, Yerevan, Republic of Armenia

Background: To study the influence of certain clinical-morphologicalfactors on periods and frequency of metastases of the male breast cancer tothe remote organs.Material and Methods: Data presented in this study is based on analysesof 94 male patients.Results: These data show that 5-year-long survival rate is lower amongpatients with regional lymph node metastases (34% and 66% respectively,P<0.002). Metastases to the remote organs were detected in about 65% ofpatients with metastases in regional lymphatic nodes in the first threeyears after the treatment. This information enables us to identify lesion ofregional lymph nodes as an extremely important prognostic factor fordisease progression. The 5-year-long survival rate is also tightly correlatedwith tumor size. Tumors smaller than 2 cm were correlated with highersurvival rates than tumors ranging between 2 and 5 cm (79.4%, 56.1%, and31.4% respectively, P<0.05). The tumors more than 5 cm metastasizedduring the first three years in 48% of cases. The study also focused on thegrade of histological malignance for the prognosis of the disease. Itsincrease significantly reduced 5-year-long survival rate of patients (85%- I,57.6%- II, 26.3%- III respectively, P<0.05).The most common histological type was invasive ductal carcinoma whichmade up 71.3% - 67 out of 94 patients. We observed such prognosticallyfavorable histological types as mucinous carcinoma of breast and tubularcarcinoma that can be considered as one of the features of breast canceramong men.The localization of remote metastases was more frequent in bones (56.5%)and in lungs (43.5%); 9 patients died from other reasons. The metastaseswere detected in the period of 5 months to 8 years after the first treatment.Conclusion: Metastatic lesion of regional lymph nodes, the size of tumorexceeding 2cm, histological malignancy high grade are negative prog-nostic factors for 5-year-long survival rate for male breast cancer patients.More than half of the patients in the study had metastatic damage of theregional lymph nodes, 76.6% of the men began treatment course withtumors larger than 2 cm. These numbers indicate also the low probabilitythat patients will seek medical attention at early stages of disease, which issomething characteristic of Armenia. More frequently, the remote metas-tases, 59.6%, was in the first three years after treatment.

PO96

METASTATIC BREAST CANCER AT DIAGNOSIS - A BREAST UNIT 5 YEAREXPERIENCE

André Costa-Pinho 1,3, Fernando Osório 1, Sandra Soares 1, DianaMonteiro 2, André Magalhães 1, Susy Costa 1, José Luís Fougo 1, José Costa-

Maia 3

1Breast Center, Hospital S. João, Porto, Portugal2 Plastic Surgery, Hospital S. João, Porto, Portugal3General Surgery, Hospital S. João, Porto, Portugal

Introduction: Of all breast cancer patients 3-10% has distant metastases atinitial presentation with a median survival between 16-24 months.Treatment of these patients has suffered considerable changes in the lastdecades but many controversies still exists, namely the role of surgery.Methods: We retrospectively reviewed the clinical records of 31 patientswith breast cancer initially diagnosed with metastases from January 2006to December 2010. Demographic data, primary and secondary tumorcharacteristics, treatment options and overall survival were analyzedusing SPSS� 17.0 (Statistical Package for the Social Sciences, SPSS Inc.,Chicago, IL).Results: In the past 5 years 31 female patients with a mean age of 57,7(�14,6) years-old were diagnosed with metastatic breast cancer atpresentation. All primary tumors were biopsied and invasive ductalcarcinoma (IDC) was diagnosed in 24 (74,4%) patients with a mean size of59,5 (�44,1) mm. Tumor grade was 2 and 3 in 95,3%. Hormonal receptors(ER and/or PR) were positive in 25 (80,6%) and HER2 was positive in 10(32,3%); there were 3 (9,7%) "triple negative" tumors.The most frequent organs for metastases were the bone in 25 (80,6%)patients, the lung in 11 (35,5%) and the liver in 10 (32,3%). Metastases inmultiple organs were found in 13 (41,9%) patients, single organ multiplemetastases in 13 (41,9%) and single metastasis in 5 (16,1%).Treatment options were chemotherapy in 27 (87,1%) - AC regimen in 17(63,0%); hormonal therapy in 22 (71,0%); trastuzumab in 7 (22,6%);radiotherapy in 22 (71,0%) - mainly for bone metastases; primary tumorremoval in 21 (67,7%) - 17 mastectomies and 4 breast conservativesurgeries; axillary dissectionwas done in 12 (38,7%); and secondary tumorremoval in 5 (16,1%) patients. The first treatment option was systemic(chemo and/or hormonal therapy) in 29 (93,6%) patients.Overall 1-year survival was 76,9% and 2-year survival was 52,2%. 1-yearsurvival after primary tumor removal was 88,9% comparing to 50,0%without removal. Only 2 (6,4%) patients are presently alive withoutevidence of disease after 24 and 9 months of follow up.Conclusions: In our experience current treatment options for primarymetastatic breast cancer provides satisfactory control of the disease withan expected median survival of approximately 24 months. A multidisci-plinary decision team is obligatory to provide the best treatment options tothese patients.

PO97

TRENDS IN INCIDENCE OF LATE-STAGE BREAST CANCER FOLLOWINGINTRODUCTION OF ORGANISED MAMMOGRAPHY SCREENING IN ITALYBY IMPACT WORKING GROUP

Fabio Falcini 1, Flavia Foca 1, Lauro Bucchi 1, Silvia Mancini 1, CarloNaldoni 3, Donella Puliti 2, Eugenio Paci 21Romagna Cancer Registry, IRST, Meldola, Forlì, Italy2Clinical and Descriptive Epidemiology Unit, ISPO, Firenze, Italy3Department of Health, Emilia-Romagna Region, Bologna, Italy

Introduction: A decrease in the incidence of late-stage breast cancersbeing observed some years after the introduction of a mammographyscreening programme is an early surrogate indicator of disease-specificmortality reduction.Methods: As a part of the Impact project, a study evaluated the effectsthat some programmes implemented in six regions of central-northernItaly around the second half of the 1990s had on the pT stage-specificincidence of breast cancer in the female population aged 50-74 years (n ¼882,000). The year of start of screening at the municipal level wasascertained. The years of cancer registration at the municipal level weresynchronised by the year of start of screening, herein referred to as year 1.For each pT stage category and each screening year from 1 to 8, the ratio(with 95% confidence interval, 95% CI) between the observed age-stand-ardised (Europe) incidence rate and that expected based on the